2-year Study for People With Type 2 Diabetes and Overweight or Obesity

Are you living with type 2 diabetes and overweight or obesity?

If so, you may be eligible to participate in a clinical research study evaluating an investigational GLP-1 medicine (LY900043) for weight management and blood sugar control.

ABOUT THE STUDY

This is a Phase 3 study assessing how LY900043 affects body weight and blood sugar levels.

WHO MAY QUALIFY?

You may be eligible to participate if you meet all the following:

• Have type 2 diabetes

  HbA1c between 6.5% and 10.5%

  BMI of 27 or higher (classified as overweight or obesity)

  Are on stable diabetes treatment (which may include diet/exercise alone or with up to 3 oral anti-diabetes medications)

  Have not used diabetes or weight loss medications (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo — in any form, including pills or injections), Januvia (sitagliptin), or insulin within the past 3 months

  Have never had surgery for treatment of obesity

INTERESTED IN LEARNING MORE?

Click below to complete a short questionnaire to see if you may be eligible.

Study Sponsor: Eli Lilly and Company